Certara
Update in progressCERT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryHealth Information Services
Certara, Inc. and its subsidiaries deliver technology-driven services and software for biosimulation across drug discovery, preclinical and clinical research, regulatory submissions, and market access worldwide. Their offerings include model-informed drug development; PK/PD simulations; Simcyp PBPK and translational platforms; Phoenix, Pirana, and Chemaxon chemistry tools; D360 informatics; Pinnacle 21 data standards and submissions; and CoAuthor/GlobalSubmit for submissions and publications.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Jon Resnick
- Founded2008
- Employees1,515
- Websitewww.certara.com
Identifiers
- ISINUS15687V1098
- FIGIBBG00Y7BR4K3
- CUSIP15687V109
- CIK0001827090